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ABSTRACT
The, objective of the study was to compare the
effectiveness of measles vaccine by seroconversion
in vaccinated children with non-vaccinated children
of 6 to 8 months age group in a city slam community
so as to study the feasibility of advancing the age
of immunization. Live attenuated lyophilized
Schwartz strain of measles vaccine was used.
Hemagglutination inhibition (HI) antibody was
estimated. Seroconversion was defined as either the
conversion of negative to positive or a two fold rise
in titre. One hundred and thirty two children
completed the study. There was no difference in
the age, sex and nutritional status between vacci-
nated and non-vaccinated groups (p>0.7). The
seroconversion rate in the vaccinated group was
65% and in the non-vaccinated group was 26%.
The age, sex and nutritional status did not signi-
ficantly affect the seroconversion. Oar data suggest
that immunization with measles vaccine may be
effective as early as 6 months of age. Immunization
at 6 months may be needed at least for children in
densely populated areas like cities and towns.
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The current recommended age for
measles vaccination in India is after 9
months of age. About 10 to 15% of
measles infection occurs in the age
group of 6 to 8 months(1,2). The dis-
ease in infants has a high morbidity and
case fatality. This study was conducted
in the community to know the age speci-
fic effectiveness, as assessed by sero-
conversion to measles vaccine (Schwartz
strain), at 6-8 months of age with a view
to study the feasibility of immunization
at. an age earlier than 9 months.
Material and Methods
The study was a prospective randomi-
zed. trial conducted during 1988. All
children between 6-8 months of age in an
Integrated Child Development Services
(ICDS) Project Area of Madras city
were enumerated. Information regarding
date of birth, measles immunization and
infection were obtained by the Anganwadi
workers and verified by one of the
investigators from the records. Children
with acute infections at the time of recruit-
ment or those who had measles vacci-
nation, measles infection or contact with
measles within the past 2 weeks were
excluded. Oral consent was obtained from
the parents of these eligible children.
Children were weighed to the nearest
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50 g. For nutritional assessment, Well-
come classification was followed. The
individual centre in ICDS area was the
unit of randomization.
Before immunization, 2 ml of venous
blood was collected and 0.5 ml of live
attenuated lyophilized Schwartz strain of
measles vaccine 1000 TCID50 was given
to the study group. Adequate steps were
taken for the maintenance of cold chain.
Control group was not vaccinated at the
time of recruitment. Children were
observed at the end of one and two weeks
for possible reactions. Second sample
of blood was collected after 6 or more
weeks. All control group children were
vaccinated immediately after the
second sample collection. Sera were
coded and transported in ice box. They
were stored at –20°C till they were tested
at the King Institute of Preventive Medi-
cine. Antibody titre was estimated using
standard microtitration technique for
hemagglutination inhibition (HI) anti-
body(3). Seronegatives becoming positive
or a 2-fold rise in titre were considered as
seroconverted and protective(2-4). Vac-
cine effectiveness was assessed as
follows(5):
Failure rate Failure rate
Measles a m o n g  n o n -  – among
vaccine immunized immunized
(seroconver- =
sion) effec- Failure rate among non-
tiveness immunized
Out of 367 children enumerated in the
study area, 205 were recruited, randomi-
zed and the first sample of blood was
drawn. Six children, three in each group,
had measles infection between first and
second samples and were excluded.
Fisher’s exact test, Chi square test, t-test
and analysis of variance were used for the
analyses.
Results
The baseline characteristics: Sex, age and
nutritional status do not significantly
differ between the 205 who were recrui-
ted, and 162 who were not recruited
(p>0.2). The second sample was collec-
ted from 92 (70%) children between 6 to
11 weeks, and 40 (30 %) between 12 and
21 weeks. Thus only 132 children com-
pleted the study. There was no significant
difference in the distribution of sex, age
and nutritional status between those who
completed and those who failed to com-
plete the study.
The baseline characteristics between
the study and control groups are com-
pared in Table I. There was no signi-
ficant difference between the groups in the
distribution of the age, sex and nutritional
status. The distribution of post-immuni-
zation titre values of the study and control
TABLE I –Comparison of Baseline Characteristics
Between Study and Control Groups
Characteristics
Study group control group
(71) (61)*
n (%)  n (%)
Sex
Male 32 (45.1) 30 (49.2)
Female 39 (54.9) 31 (50.8)
Age
6 mo 21 (29.6) 18 (29.5)
7 mo 23 (32.4) 23 (37.7)
8 mo 27 (38.0) 20 (32.8)
Nutritional status
Normal 23 (32.4) 20 (32.8)
Under-nutrition+ 48 (67.6) 42 (67.2)
*p>0.05 for all variables.
+Includes Marasmus, Study group 1 and Control
group 3.
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TABLE II– Distribution of Post-immunization Titre Values of Study and Control
Groups According to Age and Pre-immunization Titre Values
(Reciprocals)
Age Pre-
(mo)  imm
titre
Study group
Post-immunization titre
Control group
Second sample titre
n Neg 4 8 16 32 64 128 256  n Neg 4 8 16 32 64
6 Neg 8 2 3 2 1 –
4 2 1 1  5 3 1  1
8 8 1 1 3 2 1 9 6 1 1 1
16 1 1 1 1
32 – 1 1
128 1 1 2 1 1
256 1 1 –
7 Neg 4 1 2 1 4 4
4 6 2 1 1 1 1 5 2 1 1 1
8 4 1 2 1 2 1 1
16 7 2 1 1 1 1 1 6 1 1 2 1 1
32 2 2 2 1 1
64 – 2 1 1
128 – 1 1
256 – 1 1
8 Neg 6 2 1 3 7 4 2 1
4 9 1 3 1 3 1 3 3
8 3 1 1 1 5 4 1
16 6 1 3 2 3 1 1 1
32 2 1 1 1 1
128 1 1 –
256 – 1 1
Total 71 11 5 8 17 16 12 1 1 61 29 8 7 4 5 8
groups according to age and pre-immuni- post-immunization GMT levels in either
zation titre values are shown in Table II.
The results of seroconversion and
group (p>0.05). There was a significant
increase in GMT after immunization
changes in geometric mean titre (GMT) in the study group and a significant dec-
are presented in Table III. The overall
seroconversion rate differs significantly
rease in the control group except in the
8th month. The nutritional status did
between study and control groups
(p<0.05). There was no difference in the
not significantly affect the seroconversion
conversion rates within. the age group.
or the change in GMT in the study
There was no significant difference among
group (p>0.2). Therewere no untoward
the 6, 7 and 8 months of age, in their
reaction? among immunized.
preimmunization GMT levels and also
Second sample of blood was collected
in 43 and 28 children among study group
1173
DEIVANAYAGAM ET AL. AGE FOR MEASLES IMMUNIZATION
TABLE III– Comparison of Seroconversion Rates and Changes in GMT to
Measles Vaccine Between Study and Control Groups
Study group Control group
(mo) Serocon- P r e Post- Serocon-   Pre- Post-
n verted         
GMT
n verted imm
(%) (%) GMT
6 21 14 (67) 8.00 16.54* 18 3 (17) 10.08 5.9*
7 23 13 (56) 8.24 16.49* 23 5 (22) 12.96 8.5*
8 27 19 (20) 7.80 18.19* 20 8 (40) 8.00 10.2* *
Total  71 46 (65) 8.00 17.13* 61 16 (26) 10.27 8.1**
p<0.0001. **p>0.05 (paired t-test)
and in 36 and 25 among control group
after an interval of 6-11 and 12-21 weeks,
respectively. The number of children
seroconverted for the corresponding time
intervals were 28 and 18 in the study
group and 6 and 10 in the control group.
There was no difference in the serocon-
version rates between, the two different
time intervals of blood collection in either
group. There was no significant difference
in the post-immunization GMT values
between two time intervals in study group
(p>0.05) but there was a difference in
the control group.
This study was done in the community.
The laboratory personnel were not provi-
ded the clinical details to avoid expecta-
tion bias(6). The control group was used
to assess the significance. The sero-
conversion was clinically significant as the
conversion rate was 65 %. Measles vaccine
effectiveness observed in our study in the
field was (45/61-25/71)/(45/61)=52%.
Seroconversion rates in vaccine efficacy
studies (4,7,8) (seroconversion at ideal
conditions and/or for those who have been
initially seronegative) are likely to be
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higher than the rates in vaccine effective-
ness studies (2,9-11) (studies carried out
in actual settings and include all children
for analysis).
Our data is comparable to that of few
studies for the age group of 6-8 months:
Lat in  America  (65%) and Halsey
(63 %)(7,8). However, our finding is diffe-
rent from that of others: lower rates were
reported by Katiyar (52 %), Dick (45 %),
Saha (34%) and Ruiz (47%) (9,10,12,13);
higher rates were reported from South
India (87%). Latin America (65% to
85%) and Kenya (87%) (4,7,14). Apart
from other factors, the differences in the
observationscould be due to variations in
the design, measurement and analysis of
the studies. In thepresent study, if vaccine
efficacy by seroconversion among sero-
negatives is alone considered, then the
seroconversion rate in the study group
was 29/35, i.e., 83 %, in the control group
it was 9/24, i.e., 37% and the vaccine
effectiveness in the field was 73 %.
If the interval between first and second
blood sample collection, is too long, the
possibility of subclinical infection contri-
buting to enhanced seroconversion effect
is a possible bias. This may be more so
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in the control group and thereby reduce
the effectiveness of the vaccine. There
was a high increase in the GMT level
among 8-months-old, in both the study
and control groups. This could probably
be due to sub-clinical infection. This
study confirms the finding of others
that seroconversion to  measles  i s
not  inf luenced by the  nutr i t ional
status (2,4,15,16).
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Though the vaccine effectiveness is
not high, it suggested that immunization
in India may have to be considered as
early as 6 months, at least for children
living in densely populated areas like
cities and towns where the outbreaks are
more and spread of measles is rapid (17).
They need another dose after 15 months
of age, probably at 18 months of age, along
with DPT and OPV (18,19). Close super-
vision is necessary to ensure that children
immunized before the age of 9 months do
in fact receive a second dose(20). It has
been shown by many studies that low level
of immune response in infants do not
interfere with subsequent (second) dose
of immunization (21-23).
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